Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: Life expectancy compared to women of an age-matched normal population

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 772-778

  Lambert, H E ^a   Gregory, W M ^b   Nelstrop, A E ^b   Rustin, G J S ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Long term survival; Ovarian cancer; Prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM DERIVATIVE;

ABDOMINAL RADIOTHERAPY; ADVANCED CANCER; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PERFORMANCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 4544241358     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014507.x     Document Type: Article

References (15)

1. Lambert HE, Rustin CJS, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 1993;11:440-8.
2. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997;8:327-33.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-81.
4. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
5. Gregory WM. Adjusting survival curves for imbalances in prognostic factors. Br J Cancer 1988;58:202-4.
6. Office of Population Censuses and Surveys, Mortality Statistics, 1995. London: HM Stationary Office, 1989:8-9.
7. Armitage P. Statistical Methods in Medical Research. Oxford: Blackwell Scientific, 1971, 135-8.
8. Gregory WM, Richards MA, Slevin ML, Souhami RL. A mathematical model relating response durations to amount of subclinical disease. Cancer Res 1991;51:1210-6.
9. Gregory WM. Cell proliferation and the principles of cancer therapy. In: Hall PA, Levison DA, Wright NA, eds. Assessment of Cell Proliferation in Clinical Practice. London: Springer-Verlag, 1992, 193-205.
10. Gregory WM. The evaluation of durations of response to cancer therapy. PhD Thesis, University College, London, 1993.
11. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality 1979-1995. Obstet Gynecol 1999;93:30-3.
12. Bjorge T, Engeland A, Ssndford K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian radium hospital. Acta Obstet Gynecol Scand 1998;77: 777-81.
13. Rubin SC, Randall TC, Armstrong KA et al. Ten year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4.
14. Gadducci A, Bruzzone M, Carnio F et al. Twelve year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. Int J Gynaecol Cancer 1996;6:286-90.
15. Cervantes A. Prognostic factors in advanced ovarian cancer. Int J Gynaecol Cancer 1997;7:4-8.